Persistently Increased Serum Concentration of Heart-Type Fatty Acid-Binding Protein Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure
-
- Niizeki Takeshi
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Takeishi Yasuchika
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Arimoto Takanori
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Nozaki Naoki
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Hirono Osamu
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Watanabe Tetsu
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Nitobe Joji
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Miyashita Takehiko
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Miyamoto Takuya
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Koyama Yo
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Kitahara Tatsuro
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Suzuki Satoshi
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Sasaki Toshiki
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
-
- Kubota Isao
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
Search this article
Abstract
Background Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein that is released into the circulation when the myocardium is injured. This study examined whether serial measurement of the H-FABP level provides additional prognostic information. Methods and Results Serum H-FABP levels were measured in 113 consecutive chronic heart failure (CHF) patients at both admission and discharge. The following 3 patterns of changes were identified. In 41 patients, H-FABP levels (<4.3 ng/ml) at both admission and discharge were normal (Group 1). The remaining 72 patients had high initial H-FABP levels (≥4.3 ng/ml) at admission, and in 21 of them (29%), H-FABP decreased to the normal range at discharge (Group 2), whereas 51 had persistently high H-FABP levels despite improvement in symptoms and signs of CHF (Group 3). There were 33 cardiac events (29%) during the follow-up period, and Group 3 had significantly higher cardiac event rates than Groups 1 and 2 (p=0.0002). Group 3 had the highest cardiac risk among the groups (hazard ratio 5.68, p=0.012). Conclusion Serial measurement of the H-FABP level is a new monitoring tool that provides information to guide optimal therapy and management of CHF patients. (Circ J 2008; 72: 109 - 114)<br>
Journal
-
- Circulation Journal
-
Circulation Journal 72 (1), 109-114, 2008
The Japanese Circulation Society
- Tweet
Keywords
Details
-
- CRID
- 1390282680079610496
-
- NII Article ID
- 110006533924
-
- NII Book ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
- http://id.crossref.org/issn/13469843
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed